The indigenous vaccine, DengiAll, has been developed by Panacea Biotec; the phase 3 clinical trial is being conducted by ICMR and the pharma company on over 10,000 participants across 18 States The indigenous vaccine, DengiAll, has been developed by Panacea Biotec; the phase 3 clinical trial is being conducted by ICMR and the pharma company on over 10,000 participants across 18 States Health Health News, Wellbeing Tips, Diseases, Treatment and Nutrition | The Hindu
First-ever phase-three clinical trial for dengue vaccine initiated in India
